In vivo CAR-T cell therapy: latest updates from 2025 ASH annual meeting - PubMed
6 hours ago
- #hematological malignancies
- #delivery systems
- #in vivo CAR-T
- In vivo CAR-T cell therapy addresses limitations of ex vivo methods, such as long manufacturing times, high costs, and restrictive patient eligibility.
- Novel delivery systems presented at the 2025 ASH meeting include engineered lentiviral vectors and non-viral platforms like lipid nanoparticles.
- Therapeutic applications of in vivo CAR-T therapy are expanding beyond oncology to include autoimmune diseases.
- The approach enables direct engineering of immune cells within patients, offering immediate administration and improved scalability.